NDA 022012 · Waylis Therap
Coreg Cr
Carvedilol Phosphate · Oral
Last checked: Nov 19, 2026Latest source record: Jul 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 20, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
238
43 Phase 3, 25 recruiting
FAERS reports
2,975
1,127 serious, 148 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 25, 2025.
COREG CR is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure. ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients. ( 1.2 ) hypertension. ( 1.3 ) 1.1 Heart Failure COREG CR is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG CR is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ] . 1.3 Hypertension COREG CR is ındicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ] .
Mechanism: Carvedilol is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2008 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form
- Oct 20, 2006 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LabelReviewLetter
4 products under this application
- COREG CR · CARVEDILOL PHOSPHATE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- COREG CR · CARVEDILOL PHOSPHATE 20MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- COREG CR · CARVEDILOL PHOSPHATE 40MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- COREG CR · CARVEDILOL PHOSPHATE 10MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Carvedilol" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT00344513 · 50,000 participants · Start Dec 16, 2002
Drug: Beta-blockers including Carvedilol; ACE inhibitors · For: Heart Failure, Congestive
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT03646357 · 2,895 participants · Start Oct 1, 2018 · Primary completion Apr 4, 2025
Drug: Betablocker · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Arendal, Norway; Bergen, Norway; Bodø, Norway · 20 sites in all
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection FractionPivotal-lookingActive, not recruiting
Bispebjerg HospitalAcademic, hospital or other
NCT03778554 · 2,760 participants (planned) · Start Dec 17, 2018 · Primary completion Apr 1, 2025
Drug: Metoprolol Succinate; Bisoprolol and 2 more · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular OutcomesPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT05931276 · 2,540 participants (planned) · Start May 22, 2024 · Primary completion Dec 31, 2026
Drug: Metoprolol Succinate; Carvedilol · For: End-Stage Kidney Disease; End-Stage Renal Disease
Sites: Long Beach, California; Aurora, Colorado; West Haven, Connecticut · 18 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness309
- fatigue298
- drug ineffective291
- dyspnoea192
- nausea145
- headache142
- blood pressure increased139
- diarrhoea131
- hypotension121
- asthenia109
- malaise104
- fall92
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 499 |
| 2008 | 443 |
| 2009 | 305 |
| 2010 | 155 |
| 2011 | 162 |
| 2012 | 126 |
| 2013 | 145 |
| 2014 | 210 |
| 2015 | 196 |
| 2016 | 162 |
| 2017 | 124 |
| 2018 | 100 |
| 2019 | 112 |
| 2020 | 67 |
| 2021 | 34 |
| 2022 | 32 |
| 2023 | 19 |
| 2024 | 30 |
| 2025 | 34 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Coreg Cr (Carvedilol Phosphate)
2024 spending
$8.7M
Beneficiaries
1,081
4,102 claims
Per beneficiary
$8,057
$32.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,294,026 |
| 2021 | $10,430,737 |
| 2022 | $6,236,938 |
| 2023 | $9,519,887 |
| 2024 | $8,709,775 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Carvedilol.
· Can Fam Physician 1999 · Clinical Trial, Controlled Clinical Trial
- Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, et al. · J Hepatol 2022 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).
Khajuria R, Jindal A, Sharma MK, et al. · Am J Gastroenterol 2026 · Randomized Controlled Trial
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. · Lancet 2003 · Clinical Trial, Comparative Study
- Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Watanabe H, Ozasa N, Morimoto T, et al. · PLoS One 2018 · Multicenter Study, Randomized Controlled Trial
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Dargie HJ · Lancet 2001 · Clinical Trial, Multicenter Study
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.